DSGN
Income statement / Annual
Last year (2024), Design Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Design Therapeutics, Inc.'s net income was -$49.59 M.
See Design Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$834.00 |
| Cost of Revenue |
$596.00 K
|
$537.00 K
|
$466.00 K
|
$0.00
|
$5.00 K
|
$1.65 K
|
| Gross Profit |
-$596.00 K
|
-$537.00 K
|
-$466.00 K
|
$0.00
|
-$5.00 K
|
-$820.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
-21.12
|
-0.98
|
| Research and Development Expenses |
$44.35 M
|
$57.06 M
|
$48.61 M
|
$24.78 M
|
$6.06 M
|
$1.65 M
|
| General & Administrative Expenses |
$18.03 M
|
$21.13 M
|
$18.98 M
|
$11.05 M
|
$2.50 M
|
$1.09 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.03 M
|
$21.13 M
|
$18.98 M
|
$11.05 M
|
$2.50 M
|
$1.09 M
|
| Other Expenses |
-$596.00 K
|
-$537.00 K
|
-$466.00 K
|
$0.00
|
$0.00
|
-$834.00 K
|
| Operating Expenses |
$61.79 M
|
$77.65 M
|
$67.13 M
|
$35.83 M
|
$8.55 M
|
$1.91 M
|
| Cost And Expenses |
$62.38 M
|
$78.19 M
|
$67.59 M
|
$35.83 M
|
$8.56 M
|
$1.91 M
|
| Interest Income |
$12.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$596.00 K
|
$537.00 K
|
$466.00 K
|
$129.00 K
|
$5.00 K
|
$1.91 M
|
| EBITDA |
-$48.99 M |
-$66.33 M |
-$62.84 M |
-$35.70 M |
-$8.28 M |
-$139.00 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-36615.04
|
-166.67
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-36858.41
|
-2287.77
|
| Total Other Income/Expenses Net |
$12.80 M
|
$11.33 M
|
$4.29 M
|
$298.00 K
|
$276.00 K
|
-$139.00 K
|
| Income Before Tax |
-$49.59 M
|
-$66.86 M
|
-$63.31 M
|
-$35.53 M
|
-$8.28 M
|
-$2.05 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-36637.17
|
-2454.44
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$49.59 M
|
-$66.86 M
|
-$63.31 M
|
-$35.53 M
|
-$8.28 M
|
-$2.05 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-36637.17
|
-2454.44
|
| EPS |
-0.88 |
-1.19 |
-1.14 |
-0.77 |
-0.3 |
-0.0753 |
| EPS Diluted |
-0.88 |
-1.19 |
-1.14 |
-0.77 |
-0.3 |
-0.0753 |
| Weighted Average Shares Out |
$56.59 M
|
$55.98 M
|
$55.71 M
|
$45.94 M
|
$27.19 M
|
$27.19 M
|
| Weighted Average Shares Out Diluted |
$56.59 M
|
$55.98 M
|
$55.71 M
|
$45.94 M
|
$27.19 M
|
$27.19 M
|
| Link |
|
|
|
|
|
|
